Atea Pharmaceuticals, Inc.
Clinical trials sponsored by Atea Pharmaceuticals, Inc., explained in plain language.
-
New hep c pill combo takes on standard therapy in major trial
Disease control Recruiting nowThis study compares a new oral medication, Bemnifosbuvir-Ruzasvir, to the current standard treatment, Sofosbuvir-Velpatasvir, for adults with chronic hepatitis C. About 880 participants who have not taken similar drugs before will receive one of the two treatments. The main goal …
Phase: PHASE3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Experimental hepatitis c drug tested in patients with organ damage
Knowledge-focused Recruiting nowThis early-stage study looks at how a single dose of the experimental drug combination bemnifosbuvir and ruzasvir is processed by the body in people with severe kidney or liver impairment compared to healthy volunteers. The goal is to gather safety and drug-level information, not…
Phase: PHASE1 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 05:44 UTC
-
New drug interaction study recruits healthy volunteers
Knowledge-focused Recruiting nowThis study looks at how a new drug combination (BEM/RZR) affects the levels of buprenorphine/naloxone or methadone in the body. It involves 32 healthy adults who are on stable treatment for opiate withdrawal. The goal is to understand if the new drug changes how these medications…
Phase: PHASE1 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 08, 2026 12:00 UTC